Skip to main content

Advertisement

Table 3 Association of baseline serum adipokine levels and radiographic disease progression defined as an increase of ≥1 in total SHS between inclusion and 1 year

From: Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort

  Univariate model Model 1 “Base” Model 2 “Metabolic” Model 3 “Metabolic + RA” Model 4 “Metabolic + RA + steroid”
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Adiponectin Total ∆SHS ≥1 1.34 (1.03-1.76) 0.03 1.59 (1.19-2.12) 0.002 1.57 (1.16-2.13) 0.004 1.84 (1.24-2.71) 0.002 1.84 (1.25-2.72) 0.002
Erosive ∆SHS ≥1 1.34 (1.02-1.75) 0.03 1.56 (1.17-2.08) 0.003 1.54 (1.13-2.08) 0.006 1.73 (1.17-2.55) 0.006 1.73 (1.17-2.55) 0.006
Narrowing ∆SHS ≥1 1.65 (1.05-2.61) 0.03 1.79 (1.10-2.90) 0.02 1.95 (1.16-3.27) 0.01 1.91 (1.04-3.52) 0.04 1.93 (1.04-3.57) 0.04
Leptin Total ∆SHS ≥1 0.86 (0.71-1.05) 0.14 0.95 (0.76-1.18) 0.63 1.24 (0.9-1.70) 0.2 1.59 (1.05-2.41) 0.03 1.59 (1.05-2.42) 0.03
Erosive ∆SHS ≥1 0.88 (0.72-1.07) 0.19 0.96 (0.77-1.20) 0.69 1.29 (0.93-1.78) 0.12 1.68 (1.11-2.56) 0.01 1.69 (1.11-2.57) 0.01
Narrowing ∆SHS ≥1 0.93 (0.66-1.3) 0.66 0.93 (0.64-1.35) 0.70 1.09 (0.63-1.87) 0.76 1.1 (0.58-2.09) 0.76 1.10 (0.58-2.08) 0.77
Visfatin/NAMPT Total ∆SHS ≥1 1.22 (0.99-1.51) 0.06 1.20 (0.97-1.49) 0.09 1.2 (0.95-1.49) 0.12 1.09 (0.81-1.46) 0.57 1.09 (0.81-1.46) 0.58
Erosive ∆SHS ≥1 1.25 (1.01-1.54) 0.04 1.23 (0.99-1.52) 0.06 1.22- (0.98-1.53) 0.08 1.14 (0.85-1.53) 0.37 1.14 (0.85-1.54) 0.37
  Narrowing ∆SHS ≥1 1.17 (0.82-1.67) 0.39 1.16 (0.81-1.67) 0.41 1.05 (0.73-1.53) 0.79 1.12 (0.72-1.75) 0.62 1.13 (0.72-1.77) 0.6
  1. OR, odds ratio; 95% CI, 95% confidence interval. Total patient number, 530.
  2. Data are unadjusted and adjusted odds ratios with p values. Bold P values are significant.
  3. Radiographic progression is defined as variation in total SHS between inclusion and 1 year (total ∆SHS) ≥1.
  4. Erosive radiographic progression is defined as variation in erosive SHS between inclusion and 1 year (erosive ∆SHS ≥1).
  5. Narrowing radiographic progression is defined as variation in narrowing SHS between inclusion and 1 year (narrowing ∆SHS ≥1).
  6. Multivariate models:
  7. Model 1 (“base”): sex + age (n = 530).
  8. Model 2 (“metabolic”): Model 1 + BMI + HOMA-IR index (n = 497).
  9. Model 3 (“metabolic + RA”): Model 2 + CRP level + DAS28-ESR value + HAQ score + RF status + anti-CCP antibody status + presence of radiographic changes at inclusion (n = 344).
  10. Model 4 (“metabolic + RA + steroid”): Model 3 + steroid prescription at inclusion (n = 344).
  11. The following variables were log-transformed: CRP level, HAQ score, serum adipokine levels.